Donfrancesco E, Yvorel V, Casteillo F, et al. - Because the presence of multiple synchronous lung cancer with the same histopathological type for a people is a common situation and an issue for staging. Pathological criteria exist to distinguish multiple primaries from intra-pulmonary metastases of the same tumor, but they want standardization. Researchers sought to determine how molecular analysis with a limited next-generation sequencing panel could bring further information for tumor staging in this setting by comparing it with histopathological examination. They examined 24 people with a total of 50 tumor nodules and tested them molecularly. For molecular analysis, progression-free survival was not related to the proportion of progression-free individuals was at the limits of significance whereas the appearance of lepidic component, architectural concordance, and the concordance of comprehensive histologic assessments. Finding suggests that in most people, a limited NGS panel brings supplementary data to classify synchronous lung adenocarcinoma. It was shown that molecular staging seems in accordance with progression-free survival. The only histopathological examination might not be perfect enough to evaluate the right staging for synchronous tumors. Moreover, it was also suggested that perhaps TTF-1 immunohistochemistry, for the rare discrepant cases, a surrogate to molecular analysis.